Men's Health
What Is a Normal Testosterone Level in Menopause?
Most women don't realize testosterone starts declining a full decade before their last period — and that low levels can explain fatigue, low libido, and mood changes that estrogen therapy alone doesn't fix. Understanding what's normal for testosterone in menopause is the first step toward actually doing something about it.
What Is a Normal Testosterone Level in Menopause?
For most women in menopause, a total testosterone level between 10–70 ng/dL is considered within the broad reference range, but the clinically meaningful window is narrower — roughly 20–50 ng/dL. The main caveat: labs vary widely in how they measure low-level testosterone, making free testosterone and SHBG equally important. Women on oral estrogen therapy or with thyroid dysfunction are a notable exception, as both conditions alter SHBG and distort total testosterone readings.
---
Why Testosterone Matters After Menopause
Testosterone is rarely the first hormone that comes to mind when discussing menopause — estrogen and progesterone dominate that conversation. But testosterone plays a far larger role in female health than most people, including many clinicians, acknowledge.
In women, testosterone is produced by the ovaries, adrenal glands, and through peripheral conversion of androgen precursors like DHEA-S. By the time a woman reaches natural menopause (average age 51 in the United States), her testosterone levels have already declined by approximately 50% from peak levels seen in her 20s (Davison et al., Journal of Clinical Endocrinology & Metabolism 2005; PMID: 15827095). That decline doesn't happen overnight at menopause — it's a slow erosion across the entire fourth and fifth decades of life.
Low testosterone in menopausal women is associated with:
- Reduced libido and sexual satisfaction
- Fatigue and low motivation
- Decreased muscle mass and strength
- Mood disruption, including depression and irritability
- Cognitive complaints such as brain fog and poor word recall
- Bone density loss compounding the effects of declining estrogen
These symptoms frequently overlap with estrogen deficiency, which is why testosterone often gets missed. A woman reporting low energy and mood changes may be given more estrogen when what she actually needs is a careful look at her androgen panel — including free testosterone and SHBG.
For a broader look at how sex hormones shift across the menopausal transition, the article on what is a normal estradiol level in menopause provides useful context on the estrogen side of the equation.
---
Total Testosterone Normal Range by Age
Women's testosterone reference ranges are dramatically wider than men's, and most lab reference ranges were historically derived from male populations or small female cohorts. More recent data — particularly from the Endocrine Society and the Australian Longitudinal Study on Women's Health — has helped sharpen the picture.
| Age Range | Total Testosterone (ng/dL) | Clinical Notes |
|---|---|---|
| 20–30 | 20–75 ng/dL | Peak androgen production |
| 30–40 | 18–60 ng/dL | Gradual DHEA-S-driven decline begins |
| 40–50 (perimenopause) | 12–50 ng/dL | Accelerated decline; SHBG often rises |
| 50–60 (early postmenopause) | 10–40 ng/dL | Ovarian testosterone production largely ceases |
| 60+ | 7–30 ng/dL | Adrenal androgens become primary source |
These ranges are composites from multiple population studies (Davis et al., Menopause 2019; PMID: 31453973). It's worth noting that absolute testosterone values alone are insufficient. A woman with a total testosterone of 25 ng/dL but an SHBG of 120 nmol/L will have almost no free testosterone available to tissues — functionally, she is androgen-deficient despite appearing within the "normal" range on paper.
Understanding total testosterone vs free testosterone is critical in this population precisely for this reason.
---
Free Testosterone Normal Range by Age
Free testosterone — the fraction not bound to sex hormone-binding globulin (SHBG) or albumin — is the biologically active form. In women, free testosterone typically represents only 1–3% of total testosterone, which makes accurate measurement both critical and technically challenging.
Most commercial labs calculate free testosterone using a formula derived from total testosterone and SHBG — this is called the calculated free testosterone. Equilibrium dialysis is the gold-standard direct measurement method, but it's expensive and not widely available in routine clinical settings.
| Age Range | Free Testosterone (pg/mL) | Method |
|---|---|---|
| 20–30 | 1.0–6.4 pg/mL | Calculated or direct dialysis |
| 30–40 | 0.8–5.0 pg/mL | Calculated |
| 40–50 | 0.5–3.8 pg/mL | Calculated |
| 50–60 (postmenopause) | 0.3–2.5 pg/mL | Calculated |
| 60+ | 0.2–1.8 pg/mL | Calculated |
Some practitioners use the Free Androgen Index (FAI = Total T ÷ SHBG × 100) as a proxy. In postmenopausal women, an FAI below 1.0 is frequently associated with symptomatic androgen insufficiency, though the clinical cutoffs are still actively debated in the literature (Wierman et al., Journal of Clinical Endocrinology & Metabolism 2014; PMID: 25279570).
Rising SHBG is a particular problem for menopausal women. Oral estrogen therapy (but not transdermal estrogen) significantly raises SHBG, which in turn reduces free testosterone bioavailability. This is one reason some women on oral HRT continue to experience low libido and fatigue — their total testosterone may look adequate while their free testosterone is effectively suppressed. Switching to transdermal estrogen or adding low-dose testosterone therapy can sometimes resolve this (Davis & Wahlin-Jacobsen, The Lancet Diabetes & Endocrinology 2015; PMID: 26358173).
---
How Low Testosterone Symptoms Overlap With Other Menopausal Changes
One of the genuine challenges in menopause management is that the symptoms of low testosterone are almost entirely non-specific. Fatigue, cognitive slowing, joint discomfort, mood changes, and reduced muscle mass can all be driven by estrogen deficiency, thyroid dysfunction, sleep disruption, vitamin D deficiency, iron deficiency, or low testosterone — often in combination.
This is why a panel approach matters. Looking at testosterone in isolation, without also reviewing SHBG, FSH, estradiol, thyroid panel, and basic metabolic markers, gives an incomplete picture.
For example, elevated FSH is one of the clearest hormonal signals of ovarian failure and helps contextualize low testosterone readings. The article on what is a normal FSH level in menopause walks through those reference ranges in detail. Similarly, thyroid dysfunction — particularly subclinical hypothyroidism — can masquerade as low testosterone symptoms entirely, and it affects SHBG levels directly. The resource on what is a normal thyroid level in menopause is worth reviewing alongside an androgen panel.
Joint pain is another commonly overlooked androgen-deficiency symptom — testosterone has anabolic effects on cartilage and tendon tissue. If joint pain appears or worsens in the menopausal transition, the explanation may be multifactorial.
---
Testing Testosterone: What to Ask Your Doctor
Getting an accurate testosterone measurement in women requires a few specific steps that are often skipped in standard annual labs:
- Request both total testosterone AND SHBG — free testosterone is calculated from these two values. Many labs won't include SHBG in a standard panel unless it's explicitly ordered.
- Test on the correct day if possible — for women in perimenopause who are still cycling, morning of days 8–10 of the menstrual cycle is preferred to catch the androgen peak.
- Use a sensitive assay — standard immunoassay methods are notoriously inaccurate at the low testosterone concentrations seen in women. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is significantly more accurate for low-level female testosterone and is available through Quest, LabCorp, and most academic medical centers (Stanczyk et al., Steroids 2010; PMID: 20434472).
- Account for medications — oral contraceptives, oral HRT, corticosteroids, and some antidepressants all affect testosterone metabolism or SHBG in ways that distort results.
- Retest before making treatment decisions — a single low value can reflect timing, stress, illness, or lab variability. Two low values on different days provides a more reliable picture.
---
What About DHEA-S? The Upstream Precursor
DHEA-S (dehydroepiandrosterone sulfate) is the most abundant adrenal androgen in the body, and it serves as the raw material from which both testosterone and estrogen are synthesized in peripheral tissues. It peaks in the late 20s and declines steadily — by menopause, most women have DHEA-S levels at 20–40% of their youthful peak.
Because the ovaries contribute less testosterone after menopause, adrenal DHEA-S becomes proportionally more important as a testosterone precursor. Women with very low DHEA-S who also have low testosterone often benefit from addressing the upstream precursor rather than jumping directly to testosterone therapy.
For women in the postpartum period who are noticing hormonal disruption, the article on what is a normal DHEA-S level postpartum offers a helpful comparison point for how adrenal androgens behave across reproductive transitions.
---
What This Means for Your Formula
When lab work and symptom data point toward androgen-related dysfunction in the menopausal transition, there are several evidence-based nutritional interventions worth considering — and where a personalized supplement protocol can genuinely add value.
Ashwagandha (KSM-66, 600 mg/day): A randomized controlled trial in women found that KSM-66 ashwagandha at 600 mg/day for 8 weeks significantly improved sexual function scores compared to placebo, with effects attributed partly to stress-axis modulation (cortisol reduction) that indirectly supports androgen balance (Dongre et al., BioMed Research International 2015; PMID: 26609282). Ones includes KSM-66 at the full 600 mg clinical dose — not split or diluted.
Zinc: Zinc is a cofactor in testosterone biosynthesis and acts as a mild aromatase inhibitor — reducing the conversion of testosterone to estrogen. Suboptimal zinc status is associated with lower androgen levels in both sexes. Ones includes zinc in bioavailable form, dosed to support the relevant enzymatic pathways without exceeding upper tolerable intake levels.
Vitamin D3 + K2 (MK-7): Vitamin D receptors are present on ovarian and adrenal steroidogenic cells. Observational data consistently links vitamin D deficiency with lower testosterone in women, and intervention trials in deficient populations show modest but real improvements in androgen levels with correction. Ones pairs D3 with MK-7 to support calcium partitioning alongside the hormonal benefits — a combination that's particularly relevant in postmenopausal bone and hormonal health.
Ones' AI health practitioner analyzes your blood work — including testosterone, SHBG, DHEA-S, and related markers — alongside wearable data and health history to determine which of these ingredients belong in your daily formula and at what doses. If your lab data doesn't support a particular intervention, it won't be in your capsules.
---
Key Takeaways
- Normal total testosterone in menopause falls between 10–40 ng/dL for most postmenopausal women, but the meaningful clinical window is closer to 20–40 ng/dL — values below that threshold frequently correlate with symptoms.
- Free testosterone matters more than total in this population. SHBG rises with age, oral estrogen, and liver stress, leaving less testosterone bioavailable even when total levels appear adequate.
- LC-MS/MS assays are strongly preferred over standard immunoassay for measuring low-range female testosterone — ask your lab specifically which method is being used.
- Testosterone decline starts in your 30s, not at menopause. By the final menstrual period, levels have often already halved from peak.
- Symptoms of androgen deficiency overlap heavily with estrogen deficiency, thyroid dysfunction, and micronutrient gaps — a panel approach is essential before attributing symptoms to any single hormone.
- Nutritional support for androgen balance — including ashwagandha, zinc, and vitamin D — has clinical backing and is most effective when targeted to documented deficiency or functional insufficiency rather than applied universally.